Although histological parameters were significantly improved in the treatment group, there was no significant improvement in symptoms of NUD in the treatment group compared to placebo.

INTRODUCTIONSince the signi®cant impact of Helicobacter pylori infection in the development of most gastric diseases has been established, curative therapy for the infection has been of growing clinical interest. A recent trend in curative therapy is the so-called triple therapy, 1 which consists of a proton pump inhibitor (PPI) and two different antimicrobials. Various regimens of triple therapy have been reported that utilize different combinations of proton pump inhibitor or antimicrobials, with respect to dosage and duration of treatment. 2,3 Among these, higher dosages of proton pump inhibitor have been considered to be more effective 4 and there are many reports regarding the ef®cacy of proton pump inhibitor/AC regimens using omeprazole, lansoprazole and pantoprazole. 2, 5±7 Rabeprazole, a recently developed proton pump inhibitor, has become available, and has been considered to

No abstract

No abstract

No abstract